The viewpoint discusses the advantages of on-site CAR-T manufacturing for improving patient outcomes. The current approved CAR-T treatments require off-site manufacturing, which involves transporting the patient's T-cells to an off-site facility for genetic engineering and cell expansion. This process can be time-consuming and logistically challenging. On-site CAR-T manufacturing offers several advantages, including improved patient outcomes, reduced costs, and increased patient convenience. The technology allows for the rapid production of CAR-T cells, reducing the time between patient selection and treatment. Additionally, on-site manufacturing can reduce the cost of transportation and storage of the cells. This viewpoint suggests that on-site CAR-T manufacturing has the potential to revolutionize the treatment of a range of cancers.
